Platforms for Personalized Polytherapeutics Discovery in COVID-19

Hopkins, Christopher E.; Onweni, Chidinma; Zambito, Victoria; Fairweather, DeLisa; McCormick, Kathryn; Ebihara, Hideki; Caulfield, Thomas R.; Zhang, Yu Shrike; Freeman, William D.

doi:10.1016/j.jmb.2021.166945

Cited by 4 publications

(1 citation statement)

References 94 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is noteworthy that mRNA technology can program different types of cells, including adipose-derived mesenchymal stem cells (ADSCs), human umbilical vein endothelial cells, iPSCs, human fibroblasts, and more. [93,[322][323][324] Compared to using DNA for cell reprogramming, mRNA programming offers faster expression and a lower risk of genome integration, making it an encouraging approach for clinical research.…”

Section: Other Therapiesmentioning

confidence: 99%

Engineered mRNA Delivery Systems for Biomedical Applications

Wang,

Zhu,

Gan

et al. 2024

Advanced Materials

View full text Add to dashboard Cite

Messenger RNA (mRNA)‐based therapeutic strategies have shown remarkable promise in preventing and treating a staggering range of diseases. Optimizing the structure and delivery system of engineered mRNA has greatly improved its stability, immunogenicity, and protein expression levels, which has led to a wider range of uses for mRNA therapeutics. In this tutorial review, we first provide a thorough analysis of the optimization strategies used in the structure of mRNA and then describe delivery systems in great detail. Furthermore, we summarize the latest advancements in biomedical engineering for mRNA technology, including its applications in combatting infectious diseases, treating cancer, providing protein replacement therapy, conducting gene editing, and more. Lastly, we offer a perspective on forthcoming challenges and prospects concerning the advancement of mRNA therapeutics. Despite these challenges, mRNA‐based therapeutics remain promising, with the potential to revolutionize disease treatment and contribute to significant advancements in the biomedical field.This article is protected by copyright. All rights reserved

show abstract

Section: Other Therapiesmentioning

confidence: 99%

Engineered mRNA Delivery Systems for Biomedical Applications

Wang,

Zhu,

Gan

et al. 2024

Advanced Materials

View full text Add to dashboard Cite

show abstract

The evolving role of the Caenorhabditis elegans model as a tool to advance studies in nutrition and health

Chakravarty

2022

Nutrition Research

View full text Add to dashboard Cite

Priority index for critical Covid-19 identifies clinically actionable targets and drugs

Zhang,

Wang,

Jiang

et al. 2024

Commun Biol

View full text Add to dashboard Cite

While genome-wide studies have identified genomic loci in hosts associated with life-threatening Covid-19 (critical Covid-19), the challenge of resolving these loci hinders further identification of clinically actionable targets and drugs. Building upon our previous success, we here present a priority index solution designed to address this challenge, generating the target and drug resource that consists of two indexes: the target index and the drug index. The primary purpose of the target index is to identify clinically actionable targets by prioritising genes associated with Covid-19. We illustrate the validity of the target index by demonstrating its ability to identify pre-existing Covid-19 phase-III drug targets, with the majority of these targets being found at the leading prioritisation (leading targets). These leading targets have their evolutionary origins in Amniota (‘four-leg vertebrates’) and are predominantly involved in cytokine-cytokine receptor interactions and JAK-STAT signaling. The drug index highlights opportunities for repurposing clinically approved JAK-STAT inhibitors, either individually or in combination. This proposed strategic focus on the JAK-STAT pathway is supported by the active pursuit of therapeutic agents targeting this pathway in ongoing phase-II/III clinical trials for Covid-19.

show abstract

Platforms for Personalized Polytherapeutics Discovery in COVID-19

Cited by 4 publications

References 94 publications

Engineered mRNA Delivery Systems for Biomedical Applications

Engineered mRNA Delivery Systems for Biomedical Applications

The evolving role of the Caenorhabditis elegans model as a tool to advance studies in nutrition and health

Priority index for critical Covid-19 identifies clinically actionable targets and drugs

Contact Info

Product

Resources

About